Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12282550 | 0.85 | RAB9A (0.54) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL799900 | 0.85 | ALDH1A1 (0.55) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL13118019 | 0.82 | LTA4H (0.54) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL19625332 | 0.81 | RAB9A (0.58) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL19625300 | 0.81 | RAB9A (0.56) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL19625353 | 0.81 | ATP4A (0.49) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL799889 | 0.81 | RAB9A (0.56) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL533851 | 0.81 | GAA (0.40) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL12282347 | 0.81 | LTA4H (0.58) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL26014382 | 0.81 | RAB9A (0.58) | KDM4ERAB9ASMN1; SMN2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221374-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2686317-A2 | RAF KINASE INHIBITORS | Selexagen Therapeutics, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012125981-A2 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221374-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4E 2852/4885RAB9A 1035/4885SMN1; SMN2 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.